Sonoma Pharmaceuticals Announces Commercialization of MicrocynAH® Animal Healthcare Products in Japan
14 September 2017 - 6:05PM
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), a
specialty pharmaceutical company that develops and markets unique
and effective solutions for the treatment of dermatological
conditions and advanced tissue care, today announced the
commercialization of the MicrocynAH® family of animal healthcare
products in Japan. Approved as a health care product for use
by both pet owners and veterinarians, the MicrocynAH products are
being exclusively distributed in Japan by World Pet Care Products
Company, Ltd., under the direction of the master Asian distributor,
Petagon Limited. World Pet Care Products specializes in pet
health care and consultancy services contributing to improved
quality of life in pets as well as human-animal bonding.
"It is our great honor to be afforded this wonderful opportunity
to market MicrocynAH products in the Japanese market. Based
upon my previous experience in establishing Hill's products as the
market leader in the Japanese pet food market, it is similarly my
goal to establish MicrocynAH products as the Japanese market leader
in topical wound and skin care products,” said Yoshio Koshimura,
chairman and CEO of World Pet Care Products Co., Ltd.
MicrocynAH products available include: Wound & Skin
Care Spray, Wound & Skin Care Hydrogel, Ophthalmic Gel, Eye
& Ear Wash, Anti-Itch Gel Spray with Dimethicone and Hot Spot
Gel Spray with Dimethicone. The products are well suited for
dogs, cats, horses, birds, reptiles and other animals, both large
and small. They are based upon the clinically proven
Micrcocyn® Technology with 53 patents, 30-plus clinical studies and
16 FDA clearances. This line of products has successfully treated
over ten million patients worldwide.
“It is an esteemed honor and privilege to partner with both
Petagon Limited and World Pet Care Products in our efforts to
broadly introduce the MicrocynAH products to both pet owners and
veterinarians throughout Japan. As with our successes
in establishing MicrocynAH as a market leader in the U.S., Hong
Kong, China, the Middle East and Europe, our quest in Japan is to
establish ourselves as a market leader there as well,” said Bruce
Thornton, senior vice president of international sales for Sonoma
Pharmaceuticals. “This partnership and the cash it generates
is a solid step towards our company-wide plan to breakeven next
calendar year.”
MicrocynAH will be available to Japanese retailers and
veterinarians beginning in early November, to be launched in
conjunction with an industry presentation at the University of
Tokyo by Dr. Chelsea Tripp, DVM, MS, DACVIM and a board-certified
veterinary oncologist. For more information, contact Bruce
Thornton at bthornton@sonomapharma.com.
Global Animal Wound Care MarketPet humanization
and an increasing focus on maintaining the health and well-being of
animals continue to drive the growth of the animal wound care
market globally. Changing lifestyle and an increase in
disposable incomes in emerging countries are also contributing to
higher spending on animal healthcare. According to a 2017
report from Persistence Market Research, these factors are
impacting the global animal wound care market, which is expected to
grow at 7% Compound Annual Growth Rate (CAGR) through 2025.
The market is projected to reach approximately $1.01 billion by the
end of 2025, up from $590 million in 2017.
About Sonoma Pharmaceuticals, Inc.Sonoma is a
specialty pharmaceutical company that develops and markets unique
and effective solutions for the treatment of dermatological
conditions and advanced tissue care. The company’s
products, which are sold throughout the United States and
internationally, have improved outcomes for more than five million
patients globally by reducing infections, itch, pain, scarring
and harmful inflammatory responses. The company's headquarters are
in Petaluma, California, with manufacturing operations in the
United States and Latin America. European marketing and sales
are headquartered in Roermond, Netherlands. More information can be
found at www.sonomapharma.com.
Forward-Looking StatementsExcept for historical
information herein, matters set forth in this press release
are forward-looking within the meaning of the “safe harbor”
provisions of the Private Securities Litigation Reform Act of 1995,
including statements about the commercial and technology progress
and future financial performance of Sonoma Pharmaceuticals,
Inc. and its subsidiaries (the “Company”). These forward-looking
statements are identified by the use of words such as “believe,”
“achieve,” and “strive,” among others. Forward-looking statements
in this press release are subject to certain risks and
uncertainties inherent in the Company’s business that could cause
actual results to vary, including such risks
that regulatory clinical and guideline developments may
change, scientific data may not be sufficient to meet
regulatory standards or receipt of required regulatory clearances
or approvals, clinical results may not be replicated in actual
patient settings, protection offered by the
Company’s patents and patent applications may be challenged,
invalidated or circumvented by its competitors, the available
market for the Company’s products will not be as
large as expected, the Company’s products will not be able to
penetrate one or more targeted markets, revenues will not be
sufficient to fund further development and clinical studies,
as well as uncertainties relative to varying product formulations
and a multitude of diverse regulatory and marketing requirements in
different countries and municipalities, and other risks detailed
from time to time in the Company’s filings with the Securities and
Exchange Commission. The Company disclaims any obligation to update
these forward-looking statements, except as required by law.
Sonoma Pharmaceuticals™, MicrocynAH® and Microcyn® Technology
are trademarks or registered trademarks of Sonoma Pharmaceuticals,
Inc. All other trademarks and service marks are the property of
their respective owners.
Media and Investor Contact:
Sonoma Pharmaceuticals, Inc.Dan McFaddenVP of
Public and Investor Relations(425)
753-2105dmcfadden@sonomapharma.com
Sonoma Pharmaceuticals (NASDAQ:SNOAW)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sonoma Pharmaceuticals (NASDAQ:SNOAW)
Historical Stock Chart
From Jul 2023 to Jul 2024